Avidity Biosciences Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Avidity Biosciences kazanç ve gelirin sırasıyla yıllık 41.2% ve 61.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 38.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -55.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

41.2%

Kazanç büyüme oranı

38.9%

EPS büyüme oranı

Biotechs kazanç büyümesi	24.0%
Gelir büyüme oranı	61.4%
Gelecekteki özkaynak getirisi	-55.4%
Analist kapsamı	Good
Son güncelleme	09 May 2025

Gelecekteki son büyüme güncellemeleri

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Aug 14

Recent updates

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Apr 23

Avidity Biosciences: Looks Tempting, But Wait For Interim Phase 3 Data

Feb 24

Companies Like Avidity Biosciences (NASDAQ:RNA) Are In A Position To Invest In Growth

Jan 01

Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term

Oct 02

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 16

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Aug 14

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Mar 01

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Nov 04

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Apr 08

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Nov 17

Avidity slips 20% as FDA places lead asset on partial clinical hold

Sep 27

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Jul 29

Avidity stock rises amid Chardan starting coverage with Buy

Jul 20

Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides

Jul 12

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:RNA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	301	-362	-565	-154	7
12/31/2026	19	-554	-580	-393	10
12/31/2025	9	-600	-488	-287	10
3/31/2025	9	-369	-365	-355	N/A
12/31/2024	11	-322	-308	-301	N/A
9/30/2024	10	-280	-189	-184	N/A
6/30/2024	11	-252	-159	-156	N/A
3/31/2024	11	-229	-144	-140	N/A
12/31/2023	10	-212	-123	-119	N/A
9/30/2023	10	-202	-179	-175	N/A
6/30/2023	10	-193	-173	-170	N/A
3/31/2023	10	-192	-160	-156	N/A
12/31/2022	9	-174	-139	-136	N/A
9/30/2022	8	-162	-127	-123	N/A
6/30/2022	8	-148	-117	-112	N/A
3/31/2022	8	-128	-109	-105	N/A
12/31/2021	9	-118	-99	-95	N/A
9/30/2021	10	-96	-84	-82	N/A
6/30/2021	9	-78	-72	-70	N/A
3/31/2021	8	-62	-51	-50	N/A
12/31/2020	7	-44	-38	-37	N/A
9/30/2020	6	-38	-30	-29	N/A
6/30/2020	5	-34	-26	-26	N/A
3/31/2020	4	-28	-3	-3	N/A
12/31/2019	2	-25	2	2	N/A
12/31/2018	0	-11	N/A	-10	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RNA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: RNA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: RNA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: RNA şirketinin gelirinin (yıllık 61.4% ) US pazarından (yıllık 8.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: RNA şirketinin gelirinin (yıllık 61.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: RNA 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/11 02:26
Gün Sonu Hisse Fiyatı	2025/05/09 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Avidity Biosciences, Inc. 16 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Huidong Wang	Barclays
Konstantinos Biliouris	BMO Capital Markets Equity Research
Tazeen Ahmad	BofA Global Research

Avidity Biosciences Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Consensus revenue estimates increase by 140%

Consensus revenue estimates increase by 104%

Consensus revenue estimates increase by 17%

Price target increased by 10% to US$40.80

Price target increased by 10% to US$40.80

Recent updates

Avidity Biosciences, Inc., Annual General Meeting, Jun 10, 2025

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Avidity Biosciences, Inc. Completes Enrollment in Biomarker Cohort in Phase 1/2 Fortuda™? Trial for Delpacibart Braxlosiran (Del-Brax) in People Living with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences, Inc. Announces Positive Topline Del-Zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy

Avidity Biosciences: Looks Tempting, But Wait For Interim Phase 3 Data

Avidity Biosciences, Inc. Announces 2025 Upcoming Clinical and Regulatory Highlights

Companies Like Avidity Biosciences (NASDAQ:RNA) Are In A Position To Invest In Growth

Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $300.12 million.

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophin Amenable to Exon 44 Skipping in the Phase 1/2 EXPLORE44 Trial

Avidity Biosciences, Inc. Announces Executive Changes

Avidity Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $400.9 million.

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Avidity Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

Avidity Biosciences, Inc. Appoints Simona Skerjanec as Board of Directors

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1

New minor risk - Insider selling

Director recently sold US$542k worth of stock

Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding

Consensus revenue estimates increase by 140%

Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor™ Trial

President notifies of intention to sell stock

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Full year 2023 earnings: EPS and revenues miss analyst expectations

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping

Avidity Biosciences, Inc. Plans to Initiate the Global Phase 3 Harbour Trial of AOC 1001 for Adults Living with Myotonic Dystrophy Type 1, in Mid-2024

Avidity Biosciences Reports Positive Data Demonstrating Aoc 1044 Delivers Unprecedented Concentrations of Pmo in Muscle Following A Single Dose in Healthy Volunteers from Phase 1/2 Explore44™ Trial for Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 104%

Avidity Biosciences, Inc. announced that it expects to receive $39.999993 million in funding from Bristol-Myers Squibb Company

Consensus revenue estimates increase by 17%

Price target increased by 10% to US$40.80

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Avidity Biosciences, Inc. Presents New Data Regarding Its Clinical Study of AOC 1001 for Adults with Myotonic Dystrophy Type 1

Price target increased by 10% to US$40.80

Consensus revenue estimates increase by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Provides an Update to the Status of the Partial Clinical Hold Related to Its AOC 1001 Product Candidate

Consensus revenue estimates increase by 11%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Price target decreased by 7.8% to US$40.57

Full year 2022 earnings released: US$3.34 loss per share (vs US$2.85 loss in FY 2021)

Chief Scientific Officer exercised options and sold US$224k worth of stock

Avidity Biosciences, Inc. Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

President notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$208k worth of stock

Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy

Chief Scientific Officer exercised options and sold US$831k worth of stock

Price target increased to US$44.00

Avidity Biosciences, Inc. Announces Positive AOC 1001 Phase 1/2 Marina(Tm) Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Avidity Biosciences, Inc. Announces Planned Explore44 Trial of AOC 1044 in Healthy Volunteers and Participants with Duchenne Muscular Dystrophy

Avidity Biosciences, Inc. Announces Phase 1/2 EXPLORE44 Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping

Avidity Biosciences Announces the Phase 1/2 Fortitude(Tm) Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy

Avidity Biosciences, Inc. Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial

Avidity slips 20% as FDA places lead asset on partial clinical hold

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

Consensus forecasts updated